Literature DB >> 1889176

Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of beta-lactam/beta-lactamase inhibitor combinations.

J A García-Rodríguez1, J E García Sánchez, M I García García, E García Sánchez, J L Muñoz Bellido.   

Abstract

The susceptibility of 42 strains of Xanthomonas (Pseudomonas) maltophilia to 37 antibiotics (mainly beta-lactams, aminoglycosides, and fluorinated quinolones) was tested. Xanthomonas maltophilia was resistant to most beta-lactams, with ceftazidime, moxalactam, and ICI-194008 being the most active ones. Aminoglycosides had a very modest activity, with quinolones showing only moderate activity against this species. Trimethoprim/sufamethoxazole was effective against all strains tested. We also tested the synergy of several beta-lactam/beta-lactamase inhibitors against X. maltophilia. Only aztreonam/clavulanic acid at 3:1, 1:1 and, mainly, 2:1 combinations had synergistic activity, decreasing the rate of resistance from 92.8% for aztreonam alone to 32.4% for aztreonam-clavulanic acid at 1:1 and 0% for aztreonam-clavulanic acid at 2:1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889176     DOI: 10.1016/0732-8893(91)90038-h

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  13 in total

Review 1.  Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review.

Authors:  O Nyc; J Matejková
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

2.  Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics.

Authors:  K R Forward; P A Franks; D E Low; R Rennie; A E Simor
Journal:  Can J Infect Dis       Date:  1998-01

3.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Occurrence of variants with temperature-dependent susceptibility (TDS) to antibiotics among Stenotrophomonas maltophilia clinical strains.

Authors:  P Hejnar; M Kolár; V Hájek; D Koukalová; P Hamal
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

Review 5.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia.

Authors:  J L Muñoz; M I García; S Muñoz; S Leal; M Fajardo; J A Garćia-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

Review 7.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

8.  Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.

Authors:  M Biagi; D Lamm; K Meyer; A Vialichka; M Jurkovic; S Patel; R E Mendes; Z P Bulman; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

9.  Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia.

Authors:  R Paton; R S Miles; S G Amyes
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 10.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.